Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Background: Although a variety of therapeutic approaches are available for the treatment of Parkinson's disease, challenges limit effective therapy. Among these challenges are delivery of drugs through the blood brain barier to the target brain tissue and the side effects observed during long t...
Gespeichert in:
Veröffentlicht in: | Current neuropharmacology 2016-05, Vol.14 (4), p.376-391 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: Although a variety of therapeutic approaches are available for the treatment
of Parkinson's disease, challenges limit effective therapy. Among these challenges are delivery of
drugs through the blood brain barier to the target brain tissue and the side effects observed during
long term administration of antiparkinsonian drugs. The use of drug delivery systems such as
liposomes, niosomes, micelles, nanoparticles, nanocapsules, gold nanoparticles, microspheres,
microcapsules, nanobubbles, microbubbles and dendrimers is being investigated for diagnosis and
therapy.
Methods: This review focuses on formulation, development and advantages of nanosized drug delivery systems which can
penetrate the central nervous system for the therapy and/or diagnosis of PD, and highlights future nanotechnological
approaches.
Results: It is esential to deliver a sufficient amount of either therapeutic or radiocontrast agents to the brain in order to
provide the best possible efficacy or imaging without undesired degradation of the agent. Current treatments focus on
motor symptoms, but these treatments generally do not deal with modifying the course of Parkinson's disease. Beyond
pharmacological therapy, the identification of abnormal proteins such as α -synuclein, parkin or leucine-rich repeat
serine/threonine protein kinase 2 could represent promising alternative targets for molecular imaging and therapy of
Parkinson's disease.
Conclusion: Nanotechnology and nanosized drug delivery systems are being investigated intensely and could have
potential effect for Parkinson's disease. The improvement of drug delivery systems could dramatically enhance the
effectiveness of Parkinson's Disease therapy and reduce its side effects. |
---|---|
ISSN: | 1570-159X 1875-6190 |
DOI: | 10.2174/1570159X14666151230124904 |